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Epidermolysis bullosa acquisita is an autoimmune
blistering disease of the skin characterized by IgG
autoantibodies against type VII collagen. Systemic
diseases are often associated with epidermolysis
bullosa acquisita, Crohn's disease being the most
frequent. This study sought to determine if type VII
collagen, the epidermolysis bullosa acquisita auto-
antigen, was present in normal human colon by
western blotting and immuno¯uorescence. The
290 kDa type VII collagen a chain was demonstrated
by western blotting in four normal intraoperative
colon specimens. Antibodies to type VII collagen
labeled the junction between the intestinal epithe-
lium and the lamina propria. We also used an
enzyme-linked immunosorbent assay to test sera
from patients with Crohn's disease (n = 19), ulcera-
tive colitis (n = 31), celiac disease (n = 17), rheuma-
toid arthritis (n = 15), and normal controls (n = 16).
It was found that 13 of 19 patients with Crohn's
disease and four of 31 patients with ulcerative colitis
demonstrated reactivity to type VII collagen. Sera
from control subjects, patients with celiac disease or
rheumatoid arthritis were negative. The sera from
Crohn's disease patients also reacted with type VII
collagen by immunoblot analysis. It was concluded
that patients with in¯ammatory bowel disease may
have IgG autoantibodies to type VII collagen, which
exists in both the skin and the gut. Key words: auto-
immunity/in¯ammatory bowel disease/skin bullous dis-
eases. J Invest Dermatol 118:1059±1064, 2002
I
n¯ammatory bowel disease (IBD) has numerous cutaneous
associations, including pyoderma gangrenosum, erythema
nodosum, oral ulcers, annular erythemas, and vascular
thrombosis (Raab et al, 1983). Epidermolysis bullosa acquisita
(EBA), an acquired severe subepidermal blistering skin
disease, is also recognized as one of the extraintestinal manifesta-
tions of IBD. IBD has been reported to be present in approximately
30% of cases of EBA, but many of these observations were made
before modern diagnostic criteria for EBA were established (Sherry
and Dothridge, 1962; Labeille et al, 1988). Crohn's disease (CD) is
the most frequently associated condition with EBA, noted in at
least 25 cases in the literature (Livden et al, 1978; Chan et al, 1996).
Only four cases of EBA associated with ulcerative colitis (UC) have
been reported (Hughes and Horne, 1988). EBA has been reported
in association with a number of other systemic diseases, such as
rheumatoid arthritis, Hashimoto's thyroiditis, diabetes, amyloidosis,
and systemic lupus erythematosus (Chan et al, 1996).
The pathogenesis of IBD has not been established.
Environmental factors, genetic factors, microorganisms, chemical
mediators, and defects in the gut immune system may all play a part.
There is circumstantial evidence that autoimmune mechanisms may
play an important part in IBD; however, a putative autoantigen has
not been identi®ed (Braegger and MacDonald, 1994).
Immunomodulatory drugs are used in the treatment of patients
with IBD (Hanauer, 1996). These drugs include azathioprine,
mercaptopurine, corticosteroids, cyclosporine, and in¯iximab.
These agents have effects on cellular and humoral immune
function. They also inhibit the production and action of cytokines
and in¯ammatory mediators (Hanaeur, 1996).
EBA is characterized by autoimmunity to type VII collagen.
Several investigators reported that type VII collagen was con®ned
to basement membranes beneath strati®ed squamous epithelium
such as skin, oral, anal, and vaginal mucosae (Paller et al, 1986;
Visser et al, 1993). It was reported that type VII collagen was not
present in normal colonic mucosa (Paller et al, 1986; Visser et al,
1993). More recently, punctuate type VII collagen staining was
noted in normal colonic epithelium by immuno¯uorescence (Lohi
et al, 1996). The purpose of this study was to investigate whether
normal colonic epithelium contains full-length type VII collagen
and to investigate whether patients with IBD have autoantibodies
to type VII collagen.
MATERIALS AND METHODS
Diagnosis of EBA Fifty-one patients whom we have seen in the
Dermatology Clinics at the University of North Carolina, Stanford
Medical Center and North-Western University Medical Center were
evaluated. The diagnosis of EBA was made based upon the following
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criteria: (i) an active, chronic, mechanobullous disorder; (ii) subepidermal
blisters on routine light microscopy of skin; (iii) IgG deposits detected at
the dermal±epidermal junction by routine direct immuno¯uorescence;
(iv) IgG deposits localized to the dermal ¯oor of the patient's skin when
the dermal±epidermal junction was fractured through the lamina lucida
by treatment with 1 M NaCl (Woodley et al, 1983; Gammon et al,
1992); (v) IgG deposits detected within the sublamina densa zone of the
dermal±epidermal junction using direct immunoelectron microscopy
(Yaoita et al, 1981). Patients meeting the above criteria were identi®ed
and questioned for a previous history of symptoms related to bowel
function. Previous medical records and endoscopy procedures were
reviewed. Approximately half of these patients and their incidence of
IBD were published previously (Chan et al, 1996).
Diagnosis of IBD Patients with IBD with no notable skin disease
were seen at St James Hospital and Trinity College in Dublin, Ireland by
three of the authors (N.M., D.K., and D.W.) who are faculty in the
Division of Gastroenterology. The diagnoses of CD and UC were based
on clinical evaluations, radiographic ®ndings, endoscopic studies, and
biopsies of intestinal mucosa sent for pathology.
A number of EBA patients who were identi®ed in our ®les also
carried the diagnosis of IBD, predominantly CD. The diagnosis of IBD
in these EBA patients was accepted if the diagnosis of IBD was made by
a specialist in gastroenterology, if endoscopic and biopsy studies were
performed and if the patient had been followed and treated by the
gastroenterologist for IBD for more than 1 y.
Colon extract preparation/immunoblotting Full thickness colon
samples from patients were obtained immediately after resection for
carcinoma. The normal epithelium was obtained at least 7 cm away from
areas of tumor. The samples were placed in a cold cocktail of protease
inhibitors containing phosphate-buffered saline (PBS), 10 mM
ethylenediamine tetraacetic acid, and 2 mM cysteine at pH 7.5 and at
4°C. The samples were frozen at ±80°C until western blotting or
immunostaining was performed. The samples were then washed with a
sterile solution of 2 mM ethylenediamine tetraacetic acid in cold water
three times. Colonic extracts were prepared by pulverizing the tissue
with liquid nitrogen. The pulverized tissue was then placed in sample
buffer (0.125 M Tris±HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS)
containing 10 mM dithiothreitol and 1 mM phenylmethylsulfonyl
¯uoride. The samples were then vortexed, sonicated, and boiled for
5 min. The supernatant was removed and subjected to western analysis
(vide infra).
Ten micrograms of colonic extract (per lane) were subjected to SDS±
polyacrylamide gel electrophoresis (SDS±PAGE) using a 6% slab gel.
After the protein separation by SDS±PAGE, the proteins were electro-
phoretically transferred to a nitrocellulose membrane (Towbin et al,
1977). The membrane was blocked overnight at 4°C with 5% nonfat dry
milk in 10 mM Tris±HCl, pH 7.5, 100 mM NaCl, 0.1% Tween-20
(TTBS) and then incubated for 2 h at room temperature with a
polyclonal antibody to the NC1 domain of type VII collagen diluted in
TTBS with 1% bovine serum albumin (BSA; 1:2000) (Chen et al,
1997a). The blots were washed, and then incubated for 1 h with a
peroxidase-conjugated antibody to rabbit IgG at a dilution of 1:1000 in
TTBS with 1% BSA (Sigma, St Louis, MO). The blots were then
developed using enhanced chemiluminescence (Amersham,
Buckinghamshire, U.K.). Human neonatal foreskin extract was used as a
positive control. Normal rabbit serum was used as a negative antibody
control at a dilution of 1:2000.
Immuno¯uorescence Full thickness colon samples from two patients
were obtained immediately after resection and embedded in OCT
compound. The tissue was cut on a Cryostat set at 5 mm and air-dried
on glass slides. Sections were incubated with either LH 7.2 (Sigma), a
monoclonal antibody to type VII collagen, diluted 1:25, or a polyclonal
antibody to the NC1 domain of type VII collagen, diluted 1:200, at
room temperature for 2 h. After the incubation period, the sections were
washed three times with PBS and then overlaid with ¯uorescein-
conjugated goat anti-mouse or anti-rabbit IgG (Dako, Carpinteria, CA),
diluted 1:25, and incubated at room temperature for 1 h. The sections
were then washed three times with PBS, mounted in 50% glycerol±PBS
and examined with a Zeiss ¯uorescence microscope equipped with
epilumination. Human neonatal foreskin samples sectioned and labeled
with the same antibody served as positive controls. Normal colonic
mucosa incubated with normal mouse IgG or normal rabbit serum, at
the same dilution as the primary incubation step, served as negative
controls.
In addition to immunostaining intestinal mucosa for type VII collagen,
serum samples from the patients without EBA but who had IBD were
tested for their ability to label salt-split human skin and monkey
esophagus by indirect immuno¯uorescence as previously described
(Woodley et al, 1984). Sera were diluted in PBS containing 10% BSA at
1:5 and 1:10 dilutions and tested in a ``blinded'' fashion along with
positive (EBA sera) and negative controls.
ELISA using recombinant NC1 A recently developed enzyme-linked
immunosorbent assay (ELISA) using the recombinant NC1 domain of
type VII collagen as the substrate was used to detect type VII collagen
autoantibodies in the sera of patients with IBD (Chen et al, 1997b, >c).
The ELISA was performed as described (Chen et al, 1997c). Celiac
disease sera were used as a relevant bowel disease control. Rheumatoid
arthritis sera were used as an autoimmune disease control and normal
human sera were used as a negative control. All IBD and celiac disease
patients had biopsy-proven disease. Information available on each patient
included the clinical activity of the disease at the time of blood sampling
and the level of in¯ammatory markers (erythrocyte sedimentation rate
and C-reactive protein). All of the serum samples were obtained from a
cohort of patients and normal subjects from Dublin, Ireland.
Immunoblotting of recombinant NC1 protein with CD
sera Puri®ed recombinant NC1 protein (100 ng per well) was run on
a 6% SDS±PAGE, then electrophoretically transferred on to a
nitrocellulose membrane. Cut strips of the nitrocellulose membrane were
blocked overnight at 4°C with 5% BSA in TTBS. After washing with
TTBS, the strips were incubated for 1 h at room temperature with sera
from CD patients or normal control subjects. All sera were diluted 1:50
in 1% BSA/TTBS. The strips were then washed three times with TTBS.
Immunoreactivity was detected using a horseradish peroxidase-
conjugated goat anti-human IgG (Organon-Teknika-Cappel) diluted
in TTBS with 1% BSA (1:5000) for 30 min and enhanced
chemiluminescence (Amersham).
RESULTS
Twenty-®ve percent of EBA patients have IBD IBD has
been recognized as one of the more common systemic illnesses
associated with EBA (Roenigk et al, 1971; Chan et al, 1996). We
have seen, identi®ed, diagnosed and treated 51 patients with EBA
since 1986. All 51 patients met the criteria outlined above for the
diagnosis of EBA. Based upon complete evaluations by
gastroenterologists, including endoscopy and intestinal biopsies,
12 of the 51 patients had CD and one had UC associated with
EBA. These patients had their IBD diagnosed and managed by an
independent gastroenterologist. Therefore, in our series the
incidence of IBD in these patients with EBA is 25% (Chan et al,
1996). In addition, we have four EBA patients who do not have the
diagnosis of IBD and have not sought medical care for
gastrointestinal problems, but who were unable to tolerate even
one 0.4 mg tablet of colchicine without experiencing the onset of
diarrhea and cramping. Interestingly, all but two of 13 patients with
EBA and IBD had the onset of their IBD at least 2 y before the
onset of their EBA.
Full-length type VII collagen is detectable in colonic
mucosa using western blotting Using immunoblot analysis,
we demonstrated that colonic extracts contain type VII collagen. In
Fig 1, the anti-type VII collagen antibody labeled a 290 kDa band
and a 145 kDa NC1 band in all four intraoperative colon samples
(lanes 2±5), whereas no bands were detected with normal rabbit
serum (lane 1). The 290 kDa band was demonstrated to be type VII
collagen because a comigratory band was detected in a parallel lane
of authentic type VII collagen extracted from human neonatal
foreskin (lane 6).
Type VII collagen is detectable in human colonic basement
membrane In Fig 2, we used the mouse monoclonal antibody
LH 7.2 and the polyclonal antibody to the NC1 domain of type VII
collagen to demonstrate type VII collagen immunoreactivity in the
basement membrane of the colon samples. This immunoreactivity
displayed a strong linear pattern using the NC1 antibody (Fig 2c),
and a granular pattern using the less sensitive LH 7.2 (Fig 2d).
There is no basement membrane staining in the negative control
panels using either normal rabbit (Fig 2a) or mouse sera (Fig 2b).
As expected, control normal human skin displayed a strong, linear
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pattern of distribution of type VII collagen at the dermal±epidermal
junction using the NC1 antibody (Fig 2e) or LH 7.2 (Fig 2f).
Sera from CD patients reacted with NC1 by ELISA We
previously developed a speci®c and sensitive ELISA to detect
autoantibodies circulating in the sera of patients with EBA and
bullous systemic lupus erythematosus using recombinant NC1
(Chen et al, 1997b). Using this assay, we tested the sera from
patients with CD (19), UC (31), rheumatoid arthritis (15), celiac
disease (17), or normal human subjects (16 NHS). We also included
15 EBA sera as our positive control. All sera were run in the ELISA
at a 1:200 dilution. The results of this analysis are shown in Fig 3 as
a scatter plot. The results from negative control sera (16 NHS) were
analyzed to set an appropriate threshold for this assay. All the
control sera showed very low reactivity in the ELISA with values
less than 0.25. We set 0.3 OD arbitrarily as the threshold for the
(ELISA) (horizontal line in Fig 3). All the autoimmune disease
control sera (15 rheumatoid arthritis) and gastrointestinal disease
control sera (17 celiac disease) showed low reactivity with OD
values less than the threshold. In contrast to the controls, 13 sera
from 19 CD patients and four sera from 31 UC patients exhibited
reactivity with the recombinant NC1 in the ELISA. OD values
ranged from 0.38 to 1.24. As expected, all 15 EBA sera showed the
strong reactivity for NC1 with OD ranged from 0.9 to 1.78.
In order to determine whether the ®ve sera from CD patients
that had weak reactivity in the ELISA (OD = 0.35±0.5) at dilutions
of 1:200 actually contained autoantibodies for NC1, we performed
a serum dilution titer study (Fig 4). Five sera showed increased
reactivity as the sera dilution decreased from 1:1250 to 1:10. In
contrast to this dilution-dependent reactivity for NC1, sera from
four NHS did not show altered reactivity at different dilutions in
the ELISA.
Sera from CD patients reacted with NC1 by immunoblot
analysis The CD sera were further analyzed by immunoblotting
against recombinant NC1. As shown in Fig 5, the 145 kDa
recombinant NC1 protein was recognized by seven CD sera at 1:50
dilutions (lanes 2±7) but not by normal sera (lane 1). Six sera from
CD patients that had low titer in ELISA did not react with the
Figure 1. Colonic extracts contain type VII collagen. Colonic
extracts (10 mg per well) from postoperative colon (lanes 2±5) or foreskin
extract (lane 6) were subjected to 6% SDS±PAGE and electrophoretically
transferred on to a nitrocellulose membrane, before incubation with a
polyclonal antibody to NC1 (1:2000) and horseradish peroxidase-
conjugated antibody to rabbit IgG followed by enhanced
chemiluminescence detection. Lane 1 is the postoperative colon
immunoblotted with normal rabbit serum (1:2000). The positions of the
290 kDa type VII collagen, 145 kDa NC1, and the molecular weight
marker are indicated.
Figure 2. Type VII collagen is present in the
basement membrane of colon. Colonic tissue
was cut on a Cryostat set at 5 mm and air-dried
on glass slides. Sections were incubated with
either LH 7.2, a monoclonal antibody to type VII
collagen, diluted 1:25 (panel d), or a polyclonal
antibody to the NC1 domain of type VII
collagen, diluted 1:200 (panel c), at room
temperature for 2 h, then with a ¯uorescein-
conjugated goat anti-mouse or anti-rabbit IgG,
diluted 1 : 25, and incubated at room temperature
for 1 h. Panels a and b were negative control
sections that stained with normal rabbit serum
(1:200) and normal mouse serum (1:25),
respectively. Panels e and f were positive control
human skin sections staining with NC1 polyclonal
antibody (1:200) and LH 7.2 monoclonal antibody
(1:25), respectively. The slides were mounted in
50% glycerol±PBS and examined with a Zeiss
¯uorescence microscope equipped with
epilumination. Scale bar: 200 mm.
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NC1 in the immunoblot analysis at this dilution (data not shown).
Taken together, these data show a correlation between the results
of the ELISA and the immunoblot analysis.
Indirect immuno¯uorescence on human skin and monkey
esophagus with IBD patient serum Seventeen sera from
patients with IBD that reacted with NC1 in ELISA (and no
evidence of EBA) were tested for their ability to react with frozen
sections of salt-spilt human skin or monkey esophagus. All sera
were tested at dilutions of 1:5 and 1:10. Of the 17 IBD sera tested,
none reacted with either human skin or monkey esophagus and
labeled the epidermal±dermal basement membrane zone.
Lack of correlation between IBD duration and NC1
reactivity in ELISA An attempt was made to examine if there
was a correlation with the duration of the patient's IBD and the
level of the OD reading in the ELISA. The disease duration of each
of the patients with IBD varied considerably. The shortest duration
was 8 y and the longest duration was 30 y. There was no
correlation between the ELISA OD reading and the duration of the
patient's IBD. For example, the longest duration patient who had
IBD for 30 y had an OD of 0.248, whereas the patient with the
shortest duration of IBD of 8 y had an OD of 0.502.
DISCUSSION
Patients with EBA have IgG autoantibodies to type VII collagen
(Woodley et al, 1984). By western blotting analysis, these
autoantibodies recognize two proteins in extracts of skin basement
membrane: a major protein of 290 kDa and a minor protein of
145 kDa, the NC1 domain (Woodley et al, 1988). Using a
polyclonal antibody to recombinant NC1, we demonstrated the
presence of type VII (anchoring ®bril) collagen in human colon by
western blotting. The antibody labeled both 290 kDa and 145 kDa
bands in four different samples of colon (Fig 1).
Visser et al (1993) used colon samples from four patients with
normal mucosa by colonoscopy, under observation for rectal
bleeding. These samples were subjected to direct immuno¯uores-
cence using two monoclonal antibodies against type VII collagen:
NP-76 and LH 7.2. Type VII collagen immunoreactivity, how-
ever, was seen in mucosa adjacent to adenomas and carcinomas and
Figure 3. Scatter-plot representation of
ELISA results using recombinant NC1.
Patient and control sera (as indicated along the
horizontal axis) (1:200 dilution) were incubated
with immobilized puri®ed recombinant NC1
domain of type VII collagen and the bound
antibodies were detected with an alkaline-
phosphatase-conjugated antibody against human
IgG whole molecule. Each sample was run in
triplicate and the points plotted on this graph
represent the average of the OD 405 obtained
from study serum. Similar results were obtained in
three other independent studies.
Figure 4. Titer-dependent speci®c reactivity of EBA
autoantibodies to NC1. ELISA plate immobilized with equal amount
of recombinant NC1 was incubated with increasing concentrations of
®ve CD patient sera in dot or four NHS sera in triangle. Each data point
is an average of two independent observations.
Figure 5. Immunoblot of the recombinant NC1 proteins by CD
and control sera. Puri®ed recombinant NC1 (100 ng per well) protein
was separated on 6% SDS±PAGE and transferred on to nitrocellulose
membranes before incubation with sera at a dilution of 1:50 and
horseradish peroxidase conjugated anti-human IgG (1:5000) followed by
enhanced chemiluminescence detection. Lane 1, NHS; lanes 2±8, CD
serum; lane 9, EBA serum. The location of 145 kDa of recombinant
NC1 is indicated.
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in adenomatous epithelium, close to the luminal surface, but not in
normal epithelium. More recently, Lohi et al (1996) found that
immunoreactivity for type VII collagen was con®ned to basement
membrane of colonic epithelium in a punctate manner. Previously,
other authors were unable to identify type VII collagen in colon
using EBA sera and monoclonal antibodies (Paller et al, 1986).
In our immuno¯uorescence study, we were able to identify
strong linear staining of the colonic basement membrane with a
polyclonal antibody to recombinant NC1. Immuno¯uorescent
staining of human colon for type VII collagen was probably missed
previously because low titer EBA sera were used. Alternatively, the
presence of type VII collagen in human colon was missed because
the antibodies used were directed against a protease-sensitive
domain of type VII collagen. The type VII collagen targets for these
antibodies may have been degraded by the highly ef®cient
proteolysis in gut samples after the tissues were obtained.
Both EBA and IBD are considered to be disorders of immunity.
The etiologic events leading to either disease, however, are
unknown. One theory of autoimmunity is that the rise of
autoantibodies may result from molecular mimicry between
microbial and host protein. The environment created by
nonspeci®c events that cause cellular and tissue destruction may
render normal tissue proteins immunogenic, as such these altered
proteins become autoantigens. In this study, we found that none of
the 17 IBD sera that reacted with NC1 in ELISA labeled salt-split
human skin or monkey esophagus by indirect immuno¯uores-
cence. There are several possible explanations. The ®rst is that the
ELISA is more sensitive than indirect immuno¯uorescence in
detecting low titer autoantibodies as we demonstrated previously
(Chen et al, 1997c). Another possibility is that the IBD sera bind to
certain epitopes within NC1 that are not accessible in skin
basement membrane but are available to the immune system in gut
basement membrane. In the ELISA, however, the NC1 epitopes
would be available to bind the IBD sera. As only tissue-bound
autoantibodies can become pathogenic, this may explain why none
of our 17 IBD patients developed EBA.
In our patient ®les, we identi®ed 13 patients who had both EBA
and IBD. Eleven of these 13 patients had the onset of their IBD at
least 2 y before the onset of their EBA. It is not clear why some
patients with IBD have EBA and others do not. It is conceivable
that the sequela of IBD autoantibodies binding to gut type VII
collagen (and/or other mechanisms that establish an in¯ammatory
nidus) is tissue damage in the gut, which alters in the structural
molecules in the tissue and subsequently reveals cryptic type VII
collagen epitopes that become antigenic. When autoantibodies are
then generated against these antigenic neo-epitopes in gut, in
certain patients they may bind to skin basement membrane and
invoke EBA. If this process does not occur, EBA would not
develop and the patient would only have IBD. In theory, the
process could work in the other direction such that a patient with
EBA generates autoantibodies to skin type VII collagen that results
in the revelation of type VII epitopes shared by gut basement
membrane and the induction of IBD ensues after the onset of EBA.
In this scenario, the autoantibodies to the epitope in the gut would
invoke in¯ammation and induce IBD.
In addition to the theory of pure autoimmunity causing the
pathogenesis of IBD, it has also been speculated that genes related
to IBD encode products that contribute to functional or structural
alterations in the gastrointestinal tract. These alterations may render
the tissues more susceptible to toxins, infectious agents, or
autoimmune responses (Statter et al, 1993). Therefore, in addition
to possible immune and environmental factors, genetic tendencies
to develop CD and UC may be part of their disease pathogenesis
(Satsangi et al, 1996; Hampe et al, 2001).
IBD has also been associated with circulating immune complexes
and IgG immune deposits in the intestinal mucosa (Hodgson et al,
1977; Fiasse et al, 1978). Although, the tissue damage in IBD may
be immune mediated, the condition is not strictly an autoimmune
disease because the tissue damage is not directly caused by injury to
a known autoantigen (Shanahan, 1992).
There is no conclusive evidence for a direct pathogenic role for
any antibody in IBD. In the last decade, many different
autoantibodies have been identi®ed in UC and CD patients.
These include pancreatic, anti-neutrophil cytoplasmic, anti-
erythrocyte, anti-endothelial cell, anti-Saccharomyces cerevisiae, and
anti-tropomyosin antibodies (Aldebert et al, 1997; Biancone et al,
1998; Quinton et al, 1998; Fricke et al, 1999). It is probable that
antibodies in these patients are markers of underlying mucosal
immune dysregulation or perhaps a response to gastrointestinal
microbial antigens (Targan et al, 1995). This study demonstrated
that type VII collagen antibodies are present in the sera of CD
patients. It is likely that the presence of type VII collagen represents
an epitope spreading phenomenon (Chan et al, 1998), in which
damage to the overlying mucosa exposes antigenic epitopes of the
type VII collagen molecule. These newly exposed antigenic
epitopes may then invoke the immune system to mount an
antibody response.
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